13 Einträge gefunden

1. Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy

   1. Cortes, Jorge E
   2. Heidel, Florian H
   3. Fiedler, Walter
   4. Smith, B Douglas
   5. Robak, Tadeusz
   6. Montesinos, Pau
   7. Candoni, Anna

   2020 - Forschungsinformationssystem des UKE
2. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

   1. Cortes, Jorge E
   2. Heidel, Florian H
   3. Hellmann, Andrzej
   4. Fiedler, Walter
   5. Smith, B Douglas
   6. Robak, Tadeusz
   7. Montesinos, Pau

   2019 - Forschungsinformationssystem des UKE
3. Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study

   1. Gambacorti-Passerini, Carlo
   2. Cortes, Jorge E
   3. Lipton, Jeff H
   4. Kantarjian, Hagop M
   5. Kim, Dong-Wook
   6. Schafhausen, Philippe
   7. Crescenzo, Rocco

   2018 - Forschungsinformationssystem des UKE - frei zugänglich
4. Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias

   1. Cortes, Jorge E
   2. Gambacorti-Passerini, Carlo
   3. Kim, Dong-Wook
   4. Kantarjian, Hagop M
   5. Lipton, Jeff H
   6. Lahoti, Amit
   7. Talpaz, Moshe

   2017 - Forschungsinformationssystem des UKE
5. Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib

   1. Cortes, Jorge E
   2. Jean Khoury, H
   3. Kantarjian, Hagop
   4. Brümmendorf, Tim H
   5. Mauro, Michael J
   6. Matczak, Ewa
   7. Pavlov, Dmitri

   2016 - Forschungsinformationssystem des UKE
6. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib

   1. Cortes, Jorge E
   2. Khoury, Hanna J
   3. Kantarjian, Hagop M
   4. Lipton, Jeff H
   5. Kim, Dong-Wook
   6. Schafhausen, Philippe
   7. Matczak, Ewa

   2016 - Forschungsinformationssystem des UKE
7. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib

   1. Brümmendorf, Tim H
   2. Cortes, Jorge E
   3. Khoury, Hanna J
   4. Kantarjian, Hagop M
   5. Kim, Dong-Wook
   6. Schafhausen, Philippe
   7. Conlan, Maureen G

   2016 - Forschungsinformationssystem des UKE
8. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia:results from the 24-month follow-up of the BELA trial

   1. Brümmendorf, Tim H
   2. Cortes, Jorge E
   3. de Souza, Cármino Antonio
   4. Guilhot, Francois
   5. Duvillié, Ladan
   6. Pavlov, Dmitri
   7. Gogat, Karïn

   2015 - Forschungsinformationssystem des UKE
9. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia

   1. Gambacorti-Passerini, Carlo
   2. Cortes, Jorge E
   3. Lipton, Jeff H
   4. Dmoszynska, Anna
   5. Wong, Raymond S
   6. Rossiev, Victor
   7. Pavlov, Dmitri

   2014 - Forschungsinformationssystem des UKE
10. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study

    1. Shah, Neil P
    2. Guilhot, François
    3. Cortes, Jorge E
    4. Schiffer, Charles A
    5. le Coutre, Philipp
    6. Brümmendorf, Tim H
    7. Kantarjian, Hagop M

    2014 - Forschungsinformationssystem des UKE
11. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

    1. Kantarjian, Hagop M
    2. Cortes, Jorge E
    3. Kim, Dong-Wook
    4. Khoury, H Jean
    5. Brümmendorf, Tim H
    6. Porkka, Kimmo
    7. Martinelli, Giovanni

    2014 - Forschungsinformationssystem des UKE
12. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.

    1. Khoury, H Jean
    2. Cortes, Jorge E
    3. Kantarjian, Hagop M
    4. Gambacorti-Passerini, Carlo
    5. Baccarani, Michele
    6. Kim, Dong-Wook
    7. Zaritskey, Andrey

    2012 - Forschungsinformationssystem des UKE
13. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.

    1. Cortes, Jorge E
    2. Kim, Dong-Wook
    3. Kantarjian, Hagop M
    4. Brümmendorf, Tim
    5. Dyagil, Irina
    6. Griskevicius, Laimonas
    7. Malhotra, Hemant

    2012 - Forschungsinformationssystem des UKE